INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit due to allegations of misleading investors regarding its revenue outlook and market share in the Electrophysiology (EP) segment, leading to substantial financial losses for shareholders [4][12]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Troike v. Boston Scientific Corporation and covers the period from July 23, 2025, to February 3, 2026, with a deadline for lead plaintiff applications set for May 4, 2026 [1]. - The lawsuit alleges that Boston Scientific and its executives made false statements about the company's revenue projections and downplayed risks associated with market competition and economic fluctuations [4][12]. - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year prior, and a full year net income of $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share the previous year [5]. Group 2: Financial Performance and Market Impact - The company achieved an adjusted EPS of $0.80 for Q4 2025, up from $0.70 a year ago, and a full year adjusted EPS of $3.06, compared to $2.51 the previous year [5]. - Despite these results, Boston Scientific's reported EPS of $0.45 fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17% following the announcement [5]. - The lawsuit highlights that Boston Scientific's ambitions to grow its share in the EP market at "2x the market" were not met due to increased competition affecting its market share [4].